× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   
button bars forest bayes summary
 
Treament Trials
Demonstrated or suggested benefit Inconclusive results Uncertain results Safety results
corticosteroids 13

demonstrated 15 % decrease in deaths

suggested 10 % increase in hospital discharge

inconclusive results for: deaths (time to event analysis only); clinical improvement; clinical improvement (14-day); clinical improvement (time to event analysis only); clinical worsening; death or ventilation; ventilation; superinfection; serious adverse events--
remdesivir 6

demonstrated 32 % increase in clinical improvement

suggested 49 % increase in clinical improvement (14-day)

suggested 64 % increase in clinical improvement (28-day)

suggested 29 % increase in clinical improvement (7-day)

suggested 29 % decrease in serious adverse events

inconclusive results for: deaths; deaths (time to event analysis only); clinical improvement (time to event analysis only); death or ventilation; ventilation; AE leading to drug discontinuation--
hydroxychloroquine 32 noneinconclusive results for: deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (time to event analysis only); clinical worsening; death or ventilation; PCR-negative conversion; PCR-negative conversion (14-day); PCR-negative conversion (time to event analysis only); radiologic improvement (7-day); ventilation; ventilation (time to event analysis only); ICU admission; cardiac arrest; abnormal ECG findings; adverse events; arrhythmia--
convalescent plasma treatment 12 noneinconclusive results for: death or transfer to ICU; deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (28-day); clinical worsening; PCR-negative conversion (7-day); serious adverse events--
interferon 6

demonstrated 3.4-fold increase in clinical improvement (time to event analysis only)

inconclusive results for: deaths; clinical improvement; clinical worsening; death or ventilation; hospital discharge; PCR-negative conversion (time to event analysis only); ventilation; ICU admission; adverse events--
anti-interleukin-6 22

demonstrated 38 % decrease in death or ventilation

inconclusive results for: death or transfer to ICU; deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (28-day); clinical improvement (time to event analysis only); clinical worsening; hospital discharge; ventilation; ICU admission; off oxygenation; superinfection--
lopinavir/ritonavir 5

suggested 65 % increase in clinical improvement (14-day)

demonstrated 3.2-fold increase in PCR-negative conversion

demonstrated 4.4-fold increase in PCR-negative conversion (time to event analysis only)

suggested 49 % decrease in serious adverse events

inconclusive results for: death or transfer to ICU; deaths; clinical improvement; clinical improvement (28-day); clinical improvement (7-day); clinical improvement (time to event analysis only); clinical worsening; hospital discharge; PCR-negative conversion (14-day); PCR-negative conversion (7-day); radiologic improvement (14-day); radiologic improvement (7-day); adverse events--
anakinra 2 noneinconclusive results for: death or transfer to ICU; clinical worsening--
colchicine 3 noneinconclusive results for: deaths; clinical worsening; ventilation--
anticoagulant 2 noneinconclusive results for: deaths; deaths (time to event analysis only)--
Vitamin D 5

demonstrated 97 % decrease in ICU admission

inconclusive results for: deaths; death or ventilation; PCR-negative conversion--

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons